== For nonspecific stimulation, splenocytes from hu-mice were stimulated ex palpitante with PMA (phorbol 12-myristate 13-acetate) (50 ng/ml) and ionomycin (1 M) (Sigma-Aldrich) for 4 hours in the presence of brefeldin A (Biolegend). presence of cART reduced the size of HIV-1 reservoirs in lymphoid tissues and delayed HIV-1 rebound after cART cessation in the HIV-1infected hu-mice. Quercetin-7-O-beta-D-glucopyranoside We conclude that low levels of IFN-I signaling contribute to HIV-1associated immune dysfunction and foster HIV-1 persistence in cART-treated hosts. Quercetin-7-O-beta-D-glucopyranoside Our results suggest that blocking IFNAR may provide a potential strategy to enhance immune recovery and reduce HIV-1 reservoirs in individuals with sustained elevations in IFN-I signaling during suppressive cART. == Introduction == Type I interferons (IFN-I) are critical for controlling disease infections (1, 2), but they also contribute to impaired host immunity and disease persistence (3, 4). The precise role of IFN-I during chronic HIV-1 infection remains unclear (5, 6). HIV-1 infection induces widespread expression of IFN-I and IFN-stimulated genes (ISGs) (7, 8). It has been reported that IFN-I can suppress HIV-1 replication in vitro (5), and the major antiHIV-1 restriction factors are encoded by ISGs (5). In addition , IFN-I has been shown to inhibit early HIV-1 infection in humanized mice (hu-mice) (9) and SIV infection in rhesus macaques in palpitante (10). These observations suggest that a robust IFN-I response helps to control or limit initial HIV-1 and SIV contamination. IFN-I has also been implicated in the immunopathogenesis of AIDS during chronic HIV-1 infection (5, 6). Studies using nonhuman primate versions have documented that sustained IFN-I signaling is associated with pathogenic SIV infection (1114). IFN-I is induced during the acute phase of SIV infection in both pathogenic (rhesus macaques or pigtail macaques) and nonpathogenic hosts (African green monkeys or sooty mangabeys). However , compared with the nonpathogenic natural SIV infection, pathogenic SIV contamination leads to AIDS development, associated with sustained IFN-I signaling (1114). Furthermore, studies in HIV-1infected patients indicate that expression of IFN-I and ISGs is correlated with a higher level of viral fill, enhanced hyperimmune ST16 activation, and faster disease progression (8, 1517). Using the mouse model of lymphocytic choriomeningitis virus prolonged infection, it is reported that blocking of IFN-I signaling by IFNAR antibody can Quercetin-7-O-beta-D-glucopyranoside reverse immune suppression, bring back lymphoid structures, and speed up clearance from the virus (3, 4). Government of exogenous IFN- can lower HIV-1 burden in HIV-1infected patients but neglect to show a significant benefit in HIV-1 disease progression (6). Interestingly, recent studies report that the government of IFN- in HIV-1monoinfected patients or patients coinfected with HIV-1 and hepatitis C disease (HCV) leads to reduction of cell-associated viral RNA and DNA in the blood (1821). However , Quercetin-7-O-beta-D-glucopyranoside other studies in HIV-1infected patients indicate that persistent expression of ISGs is correlated with higher viral load, enhanced hyperimmune activation, and faster disease progression (8, 1517). In addition , government of IFN- to patients also leads to a decrease in CD4 To cell count number (18, 21) and enhanced CD8 To cell activation (22) in the blood. Moreover, despite effective suppression of HIV-1 replication with combined antiretroviral therapy (cART), abnormally elevated IFN-I signaling persists in some patients even under extensive cART (23, 24), which may impede the reversion of hyperimmune activation and immune recovery in all those immune nonresponder patients (25). These reports highlight that IFN-I may play important but complex roles in HIV-1 prolonged infection and pathogenesis. In the present study, we developed an antibody against human IFN-/ receptor 1 (-IFNAR1) to specifically block IFN-I signaling. We found that IFNAR blockade during prolonged HIV-1 contamination reversed Quercetin-7-O-beta-D-glucopyranoside HIV-1induced immune hyperactivation, rescued antiHIV-1 immune responses, and reduced the size of HIV-1 reservoirs in lymphoid tissues in the presence of cART. Our results suggest that blocking IFNAR will provide a book strategy to enhance immune recovery and to reduce HIV-1 reservoirs in all those patients with sustained IFN-I signaling during suppressive cART. == Results == == cART efficiently suppresses HIV-1 replication but fails to clear HIV-1 reservoirs in hu-mice, correlated with low levels of ISG expression. == To functionally define the role of IFN-I in HIV-1 prolonged infection and pathogenesis, we used humanized mice with a functional human being immune system (hu-mice) for modeling HIV-1 contamination and immunopathogenesis (26, 27). We while others have previously reported that persistent HIV-1 infection in hu-mice led to induction of IFN-I signaling, CD4 To cell depletion, aberrant immune activation, and expression from the exhaustion marker PD-1 on T cells (2729). As in human patients, cART can efficiently inhibit HIV-1 replication in hu-mice (30, 31). We discovered that plasma viremia decreased to undetectable levels ( <400 genome copies/ml) in all HIV-infected hu-mice within 3 weeks after cART treatment (Figure 1A). HIV-1 replication in lymphoid organs was also effectively inhibited by cART (Figure 1B). However , because observed in some patients (23, 24), cART failed.